Demonstrates high affinity for the kainate receptor subtype hGluR5 (Ki = 0.24 nM) and 600-4000-fold selectivity over both the AMPA receptor subtypes and the homomeric kainate receptor hGluR6.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 325.06. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.08 mL||15.38 mL||30.76 mL|
|5 mM||0.62 mL||3.08 mL||6.15 mL|
|10 mM||0.31 mL||1.54 mL||3.08 mL|
|50 mM||0.06 mL||0.31 mL||0.62 mL|
References are publications that support the products' biological activity.
Jane et al (1997) Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J.Med.Chem. 40 3645 PMID: 9357531
Patneau et al (1992) Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine. J.Neurosci. 12 595 PMID: 1371315
Swanson et al (1998) Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol.Pharmacol. 53 942 PMID: 9584222
Wong et al (1994) Willardiines differentiate agonist binding sites for kainate-versus AMPA-preferring glutamate receptors in DRG and hippocampal neurones. J.Neurosci. 14 3881 PMID: 7515954
If you know of a relevant reference for (S)-(-)-5-Iodowillardiine, please let us know.
View Related Products by Product Action
Keywords: (S)-(-)-5-Iodowillardiine, supplier, potent, subtype, selective, kainate, agonists, Glutamate, Kainate, Receptors, iGluR, Ionotropic, Kainate, Receptors, Kainate, Receptors, Tocris Bioscience
1 Citation for (S)-(-)-5-Iodowillardiine
Citations are publications that use Tocris products. Selected citations for (S)-(-)-5-Iodowillardiine include:
Pansiot et al (2010) Neuroprotective effect of inhaled nitric oxide on excitotoxic-induced brain damage in neonatal rat. Proc Natl Acad Sci U S A 5 e10916 PMID: 20532231
Do you know of a great paper that uses (S)-(-)-5-Iodowillardiine from Tocris? If so please let us know.
Reviews for (S)-(-)-5-Iodowillardiine
There are currently no reviews for this product. Be the first to review (S)-(-)-5-Iodowillardiine and earn rewards!
Have you used (S)-(-)-5-Iodowillardiine?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.